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Abstract
Background:  Oligomeric and fibrillar aggregates of the amyloid β-peptide (Aβ) have been
implicated in the pathogenesis of Alzheimer's disease (AD). The characterization of Aβ assemblies
is essential for the elucidation of the mechanisms of Aβ neurotoxicity, but requires large quantities
of pure peptide. Here we describe a novel approach to the recombinant production of Aβ. The
method is based on the coexpression of the affibody protein ZAβ3, a selected affinity ligand derived
from the Z domain three-helix bundle scaffold. ZAβ3 binds to the amyloidogenic central and C-
terminal part of Aβ with nanomolar affinity and consequently inhibits aggregation.
Results: Coexpression of ZAβ3 affords the overexpression of both major Aβ isoforms, Aβ(1–40)
and Aβ(1–42), yielding 4 or 3 mg, respectively, of pure 15N-labeled peptide per liter of culture. The
method does not rely on a protein-fusion or -tag and thus does not require a cleavage reaction.
The purified peptides were characterized by NMR, circular dichroism, SDS-PAGE and size
exclusion chromatography, and their aggregation propensities were assessed by thioflavin T
fluorescence and electron microscopy. The data coincide with those reported previously for
monomeric, largely unstructured Aβ. ZAβ3 coexpression moreover permits the recombinant
production of Aβ(1–42) carrying the Arctic (E22G) mutation, which causes early onset familial AD.
Aβ(1–42)E22G is obtained in predominantly monomeric form and suitable, e.g., for NMR studies.
Conclusion: The coexpression of an engineered aggregation-inhibiting binding protein offers a
novel route to the recombinant production of amyloidogenic Aβ peptides that can be
advantageously employed to study the molecular basis of AD. The presented expression system is
the first for which expression and purification of the aggregation-prone Arctic variant (E22G) of
Aβ(1–42) is reported.
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Background
Alzheimer's disease (AD) is the most common neurode-
generative disorder, currently afflicting about 20 million
people worldwide, with increasing prevalence in an age-
ing society [1]. AD is characterized by large extracellular
deposits of senile plaques in the brain, consisting of aggre-
gated, fibrillar amyloid β-peptide (Aβ) [2,3]. Extensive
evidence supports a critical role of soluble intermediary
Aβ oligomers in the induction of synapse dysfunction and
neurodegeneration [3-6]. Aβ originates from proteolytic
processing of the amyloid precursor protein (APP) [7].
APP is cleaved by the membrane associated β- and γ-secre-
tases that generate a number of differently sized peptides,
of which Aβ(1–40) and Aβ(1–42) are most abundant.
Aβ(1–42) is considerably more neurotoxic than Aβ(1–
40), in agreement with its increased hydrophobicity and
tendency to aggregate. Mutations within Aβ are associated
with familial AD and cerebral amyloid angiopathy. One
example is the Arctic (E22G) mutation, which entails
enhanced Aβ protofibril formation and fibrillation and
causes typical AD neuropathology [8,9].
Despite the fact that much effort has been put into Aβ-
related research, many questions still need to be
answered. Most importantly, the precise mechanisms of
Aβ toxicity remain to be understood [3]. In this context,
an inventory of oligomeric and protofibrillar Aβ species
would be desirable, detailing their biophysical properties
and contributions to neurodegeneration. The extension
and refinement of existing structural data on Aβ oligomers
and fibrils [10-12] would help to derive structure-toxicity
relationships and thus support AD drug discovery efforts.
The accessibility of large amounts of Aβ peptide is a pre-
requisite for these studies.
The majority of research using Aβ peptides within the
areas of biochemistry, biophysics and cell biology is con-
ducted with synthetic peptides. An alternative to chemical
synthesis is recombinant expression in Escherichia coli,
which is advantageous because of its low cost, the fast
growth to high expression levels and the availability of
established cloning and expression protocols [13].
Recombinant expression is particularly attractive for struc-
tural biology projects, as it enables the production of mil-
ligram quantities of isotope or seleno-methionine labeled
peptide for structure determination by nuclear magnetic
resonance (NMR) spectroscopy or x-ray crystallography at
reasonable cost.
Prokaryotic expression and purification of highly amy-
loidogenic peptides such as Aβ has proven difficult due to
their small size, their tendency to aggregate and the toxic-
ity of the formed aggregates [14]. Protein fusions, which
might protect from proteolysis and enhance solubility, are
typically used to tackle these problems [13,15,16]. The
expression of Aβ(1–40) or Aβ(1–42) fused to segments of
a surface protein from the malaria parasite Plasmodium fal-
ciparum  [17], maltose binding protein [18], ubiquitin
[19], GroES-ubiquitin [20], trigger factor-ubiquitin [21],
and hen egg white lysozyme [22] has been reported. In
order to obtain Aβ unaffected by the tag, its removal by
site specific proteolysis is an inevitable additional purifi-
cation step in all of these cases. The proteolytic cleavage
reaction is cost-intensive, requires time-consuming opti-
mization and necessitates post-reaction clean-up, which
further reduces the attainable yield.
An alternative method to increase the yield of trouble-
some target proteins is coexpression with proteins that
stabilize the target, assist with its folding, or prevent its
aggregation [23]. This technique has permitted heterolo-
gous expression of macromolecular complexes, whose
components could not be obtained individually [24-27].
Co-overexpression of molecular chaperones can increase
the yield of targets to varying extents [28,29].
Here we present a novel approach to the recombinant pro-
duction of amyloidogenic Aβ peptides. Aβ is obtained by
coexpression with an engineered binding protein that spe-
cifically binds and stabilizes the monomeric peptide. The
binding protein, termed ZAβ3, belongs to the class of affi-
body affinity ligands [30,31]. Affibody proteins have
found applications in biotechnology, biochemical assays,
disease diagnosis and therapy [31]. They are selected by
phage display from libraries based on the 58 amino acid
three-helix bundle scaffold of the Z domain derived from
staphylococcal protein A [32]. ZAβ3 is a disulfide-linked
homodimer of affibody subunits that binds monomeric
Aβ with nanomolar affinity [33] (Figure 1). In contrast to
the majority of Aβ-antibodies [34], ZAβ3 targets the highly
amyloidogenic central and C-terminal part of Aβ (residues
17–36). This region adopts a β-hairpin conformation
upon binding and is buried within a hydrophobic tunnel-
like cavity formed by ZAβ3. Consequently, Aβ oligomeriza-
tion and fibrillation are inhibited by stoichiometric con-
centrations of ZAβ3 [33].
The concept of producing Aβ by recombinant coexpres-
sion with ZAβ3  offers several potential advantages: (i)
Binding of the coexpressed ZAβ3 to the amyloidogenic
sequence region of Aβ could retain the peptide in a mon-
omeric state during expression and the initial purification
steps, thereby preventing any cell toxicity exerted by aggre-
gates and facilitating purification. (ii) Aβ is largely
unfolded in its unbound monomeric state [35], and the
complex might therefore protect the peptide from degra-
dation. (iii) Both coexpression of auxiliary proteins and
protein fusions impose additional metabolic burden on
host cells, but the small size of the affibody scaffold limitsBMC Biotechnology 2008, 8:82 http://www.biomedcentral.com/1472-6750/8/82
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this burden, which is especially important when short
peptides such as Aβ are to be expressed.
In the present implementation of the Aβ:ZAβ3 coexpres-
sion system, Aβ is expressed tag-less, offering a particu-
larly facile route to obtain pure peptide. As a consequence,
a methionine resulting from the obligatory translation
start codon is obtained N-terminal of Aβ. The resulting
peptide will thus be referred to as MAβ below.
We report the expression and purification of 15N-labeled
MAβ(1–40), MAβ(1–42) and MAβ(1–42)E22G by ZAβ3
coexpression. The method yields pure, fibrillation-compe-
tent, monomeric peptides with conformational properties
and aggregation propensities indistinguishable from
those of the respective Aβ peptides.
Results
Expression and purification of MAβ peptides
A double cistronic coexpression vector based on the bac-
terial expression vector pACYCDuet-1 (Novagen) was
constructed. The coexpression vector contains the genes
for MAβ [MAβ(1–40), MAβ(1–42), or MAβ(1–42)E22G]
and (His)6-tagged ZAβ3 in the following order: T7 pro-
moter-1 – MAβ – T7promoter-2 – (His)6ZAβ3 – T7 termi-
nator. MAβ is effectively overexpressed and obtained in
the soluble fraction of cell lysates, indicating that its com-
plex with the disulfide-linked ZAβ3 dimer is formed and
stable in the E. coli cytosol (Figure 2, lane 2).
In the present system, the auxiliary protein ZAβ3 is (His)6-
tagged but not the target peptide, permitting the purifica-
tion of tag-free MAβ without a cleavage reaction. MAβ is
captured in complex with ZAβ3 by immobilized metal ion
affinity chromatography (IMAC) (Figure 2, lane 4), dem-
onstrating that the MAβ:ZAβ3 complex remains stable dur-
ing the initial purification steps. Resonances in the 15N
heteronuclear single quantum correlation (HSQC) NMR
spectrum of the coexpressed MAβ(1–40):ZAβ3 complex
coincide with those of the native Aβ(1–40):ZAβ3 complex,
indicating that their structures are identical (Figure 3).
MAβ is not detected in the IMAC wash fraction (Fig. 2,
lane 3). Dissociation of the complex during IMAC is con-
sequently not limiting the peptide yield.
Separation of the MAβ:ZAβ3 complex is achieved by IMAC
under denaturing conditions. Pure monomeric MAβ is
subsequently obtained by application of the denatured
peptide to size exclusion chromatography (SEC) using
native running buffer, e.g., 20 mM sodium phosphate, 50
mM sodium chloride, pH 7.2.
Structure of the Aβ(1–40):ZAβ3 complex Figure 1
Structure of the Aβ(1–40):ZAβ3 complex. Ribbon draw-
ing of the topology of the complex [33]. Aβ(1–40) is shown 
in magenta, ZAβ3 in blue. The disordered N-termini are not 
displayed. The image was generated using PyMOL (DeLano 
Scientific).
Purification of MAβ peptides Figure 2
Purification of MAβ peptides. SDS-PAGE on a 16.5% 
Tris-Tricine gel at 4°C. Lane 1: Marker. 2: Cell lysate after 
MAβ(1–40) coexpression. 3: IMAC wash fraction (10 mM 
imidazole). 4: IMAC eluate after addition of 150 mM imida-
zole, demonstrating the effective capture of the ZAβ3:MAβ(1–
40) complex. 5: Purified MAβ(1–40). 6: Purified MAβ(1–42). 
Samples were incubated for 2 min at 95°C prior to loading.BMC Biotechnology 2008, 8:82 http://www.biomedcentral.com/1472-6750/8/82
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SDS-PAGE shows a single band corresponding to the
monomeric peptide in the case of purified MAβ(1–40),
whereas two additional bands at higher molecular weight,
approximately at 12 and 15 kDa, are observed for MAβ(1–
42) (Figure 2). These bands have been observed before
and have been attributed to the SDS-induced formation of
Aβ(1–42) oligomers [4,36]. Mass spectrometry confirmed
that the bands consist of MAβ(1–42).
The peptide yield from a 1 L culture was 4 mg of MAβ(1–
40) or 3 mg of MAβ(1–42). Purification of ZAβ3 from an
MAβ(1–40) coexpression culture gave 23 mg of the
dimeric protein per 1 L of culture, indicating that ~60% of
the expressed ZAβ3  was in complex with MAβ(1–40),
whereas the rest remained unbound.
Comparison of MAβ with Aβ
Several different techniques were used to establish that
MAβ and Aβ possess identical conformational properties
and aggregation propensities. MAβ and Aβ are indistin-
guishable by SDS-PAGE (Figure 4A). The extent of SDS-
induced oligomer formation of MAβ(1–42) is the same as
for Aβ(1–42) and increases with temperature.
In SEC, which separates molecules based on their hydro-
dynamic volume, very similar elution volumes are
NMR spectroscopy of purified MAβ:ZAβ3 complex Figure 3
NMR spectroscopy of purified MAβ:ZAβ3 complex. (A) 15N HSQC NMR spectrum of the 15N-labeled MAβ(1–40):ZAβ3 
complex. The complex was obtained from coexpression and purified by IMAC (elution of the intact complex with 150 mM imi-
dazole) and SEC. (B)-(D) Comparison of the glycine region (B; boxed area in panel A) with corresponding regions of 15N 
HSQC spectra of Aβ(1–40):ZAβ3 samples in which either ZAβ3 (C) or Aβ(1–40) (D) are 15N-labeled. Sequential assignments of 
glycine resonances for the two ZAβ3 subunits and bound Aβ(1–40) are given in panels C and D, respectively. The occurrence of 
resonances at identical chemical shifts in complexes of ZAβ3 with recombinant MAβ(1–40) and native Aβ(1–40) peptides indi-
cates that the structures of the two complexes are the same. NMR was measured at 25°C at 800 MHz (A, B and D) or 900 
MHz (C) on samples containing 160 μM (A, B), 450 μM (C) or 400 μM (D) complex in 20 mM potassium (A, B) or sodium (C, 
D) phosphate, with 0.1% azide and 10% D2O at pH 7.2.
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obtained for MAβ and Aβ (Figure 4B). The elution vol-
umes correspond to a molecular weight of ~11 kDa on a
scale calibrated with globular protein standards, in agree-
ment with previous SEC studies [37]. The high apparent
molecular weight (the nominal weights of the Aβ and
MAβ peptides are in the range of 4.3 to 4.7 kDa) is
expected for a peptide that is disordered and consequently
has a larger hydrodynamic volume than a globular pro-
tein of the same molecular weight.
The secondary structure content was analyzed by circular
dichroism (CD) spectroscopy (Figure 4C). Far-UV CD
spectra of MAβ conformed to those of Aβ, featuring a min-
imum at ~198 nm that is characteristic of the predomi-
nantly random coil conformation detected in non-
aggregated Aβ peptides [38,39].
The 15N HSQC NMR spectra of MAβ(1–40) and MAβ(1–
42) strongly resemble those of Aβ(1–40) and Aβ(1–42),
respectively (Figure 5). The large majority of Aβ backbone
amide resonances are recovered at identical positions in
the MAβ spectra. Differences in chemical shifts are only
observed for residues N-terminal of Arg5. Such local shift
changes are a mandatory consequence of the modification
of the peptide sequence, in this case with the N-terminal
methionine, and reflect local changes in the electronic
environment. However, the chemical shift differences do
not demonstrate any change in peptide conformation.
The 15N HSQC spectra prove that Met35 is unoxidized, by
comparison with reference spectra for Aβ(1–40) and
Aβ(1–42) [35], in agreement with the mass spectrometry
results.
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Comparison of MAβ with Aβ Figure 4
Comparison of MAβ with Aβ. (A) SDS-PAGE using 16.5% 
Tris-Tricine gels at 21°C (lanes 1–4) or 4°C (lanes 5–8). 
Lanes 1 and 5: MAβ(1–40). 2 and 6: Aβ(1–40). 3 and 7: 
MAβ(1–42). 4 and 8: Aβ(1–42). Unlabeled lanes contain 
marker. Samples were incubated for 2 min at 95°C prior to 
loading. (B) Elution profiles of analytical SEC of MAβ(1–40) 
(red line), Aβ(1–40) (red circles), MAβ(1–42) (black line), 
Aβ(1–42) (black circles). (C) Far-UV CD spectra of MAβ(1–
40) (red line), Aβ(1–40) (red circles), MAβ(1–42) (black line), 
Aβ(1–42) (black circles). (D) Kinetics of amyloid fibril forma-
tion of MAβ(1–42) (red) and Aβ(1–42) (black) monitored by 
thioflavin T fluorescence. The average of 3 time traces is 
shown with error bars representing the maximal and minimal 
values. The peptides were used at 25 μM in 20 mM sodium 
phosphate, 50 mM sodium chloride, 10 μM thioflavin T, pH 
7.2. Temperature, 37°C. (E) and (F) Electron micrographs of 
amyloid fibrils formed by MAβ(1–42) (E) and Aβ(1–42) (F). 
Scale bar, 200 nm.BMC Biotechnology 2008, 8:82 http://www.biomedcentral.com/1472-6750/8/82
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The enhanced fluorescence emission of the dye thioflavin
T upon binding to amyloid fibrils is frequently used to
monitor fibrillation [40]. The fibrillation kinetics of
Aβ(1–42) and MAβ(1–42) are identical within the error of
the experiment (Figure 4D). The presence of amyloid
fibrils in the final steady-state of fibrillation was con-
firmed by electron microscopy (Figure 4E and 4F).
Production and characterization of MAβ(1–42)E22G
The Arctic mutant of Aβ is a particularly interesting variant
inasmuch as it links an increased tendency for protofibril
formation and fibrillation to early onset familial AD [8,9].
To our knowledge, no protocol for the recombinant pro-
duction of Aβ(1–42)E22G has been reported to date, pos-
sibly due to the extreme aggregation propensity of this
peptide variant. Coexpression of ZAβ3 permitted the pro-
duction of MAβ(1–42)E22G with a yield of 1 mg from a 1
L culture. SDS-PAGE demonstrates increased oligomeriza-
tion of MAβ(1–42)E22G compared to MAβ(1–42) (Figure
6A). The major fraction of purified MAβ(1–42)E22G is
present in monomeric form as evidenced by SEC, which
gives an elution volume of ~14 mL (Figure 6B), similar to
that of monomeric MAβ(1–40) and MAβ(1–42) (Figure
4B). Recombinant MAβ(1–42)E22G can be employed,
e.g., for NMR spectroscopy. The 15N HSQC NMR spec-
trum of MAβ(1–42)E22G is displayed in Figure 6C. As
expected, the resonances of backbone amides in the vicin-
ity of residue 22 are affected by the E22G mutation due to
the removal of one negative charge. However, the changes
are not large and the E22G mutant is also disordered in its
monomeric state.
Discussion
We have shown that coexpression of the ZAβ3 affibody pro-
tein enables recombinant production of MAβ peptides.
ZAβ3 binds to the amyloidogenic, hydrophobic central and
C-terminal region of Aβ and thus prevents peptide aggre-
gation and potential detrimental effects on cellular home-
ostasis. MAβ is released from Z Aβ3 only after an initial
purification of the complex has been achieved, limiting
the potential for adverse effects during peptide prepara-
tion.
NMR spectroscopy of MAβ Figure 5
NMR spectroscopy of MAβ. 15N HSQC NMR spectra of MAβ(1–40) (A, blue), Aβ(1–40) (A, red), MAβ(1–42) (B, blue) and 
Aβ(1–42) (B, red) at 5°C at 800 MHz. The spectra illustrate the purity of the recombinantly expressed peptides. The chemical 
shifts and sharp NMR resonances indicate that the peptides exist in disordered monomeric conformations. Resonances of 
Aβ(1–40) that are displaced as a consequence of the presence of the N-terminal methionine in MAβ(1–40) are indicated. 
Assignments were obtained from literature spectra [35,52].
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Coexpression is particularly profitable for the production
of unstructured proteins that exhibit folding coupled to
binding to the coexpressed partner [41]. The Aβ:ZAβ3 inter-
action is characterized by extensive coupled folding and
binding of both binding partners [33,42]. In addition to
increasing the thermodynamic stability of the complex's
constituents, coupled folding-binding presumably also
reduces their susceptibility to proteolytic degradation.
Just as protein fusion tags preferably should be short,
coexpression systems profit from a small size of the auxil-
iary protein, as this limits the metabolic burden. The affi-
body scaffold used for engineering ZAβ3 is particularly
small and a large fraction of the surface area is involved in
the interaction with the target [31,43]. Affibody ligands
therefore represent promising auxiliary proteins for the
development of coexpression systems, as exemplified in
this study.
In contrast to previously published methods for recom-
binant expression of Aβ [17-22,44], the present system
does not require a cleavage reaction. The reported cleav-
age reactions are time-consuming and/or expose the pep-
tide to elevated temperature (typically, 37°C), which is
detrimental to the production of aggregation-prone pep-
tides [20]. All of these methods moreover include a
reverse phase chromatography step, which necessitates
thorough subsequent disaggregation of Aβ peptides
[38,45,46]. The coexpression system avoids acidic pH and
organic solvents, and non-aggregated MAβ in buffered
aqueous solution is obtained directly from size exclusion
chromatography. Some of the expression methods previ-
Recombinant expression of MAβ(1–42)E22G Figure 6
Recombinant expression of MAβ(1–42)E22G. (A) SDS-PAGE using a 16.5% Tris-Tricine gel at 4°C. Lane 1: Marker. 2: 
MAβ(1–42). 3: MAβ(1–42)E22G. (B) Elution profile of analytical SEC of purified MAβ(1–42)E22G. (C) 15N HSQC NMR spectra 
of MAβ(1–42) (blue) and MAβ(1–42)E22G (red) at 5°C at 800 MHz. Resonances of MAβ(1–42) that are lost or displaced as a 
consequence of the E22G mutation are indicated. Assignments were obtained from literature spectra [35,52].
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ously reported have further specific disadvantages com-
pared to the present system: The cleavage reaction causes
microheterogeneities [17], Met35 is oxidized [17], the
peptide yield is lower [22], or the peptide contains addi-
tional residues at the N-terminus [44,47]. In the case of
the maltose binding protein fusion, a far greater peptide
yield has been achieved [18]. This can in part be explained
by the use of a fermentation system, which allows higher
cell densities to be reached, frequently resulting in >10-
fold the amount of purified protein in comparison to
shake flask cultures [48,49]. The maltose binding protein
fusion has only been used for production of the less aggre-
gation-prone variant Aβ(1–40) and provides peptide that
aggregates into predominantly non-fibrillar structures
[50,51].
The MAβ peptides contain a methionine N-terminal of the
Aβ sequence, originating from the translation start codon.
However, according to the biochemical and biophysical
analysis of the peptides by SDS-PAGE, SEC, NMR and CD
spectroscopy, and to their aggregation propensity and
aggregate morphology, the MAβ peptides faithfully reca-
pitulate the properties of Aβ. The present coexpression
system could be adapted to provide the peptide free of the
additional N-terminal methionine by expressing a suita-
bly tagged Aβ peptide that can be cleaved to yield the
native N-terminus. This would however delimit the ease
and cost-effectiveness of the method. Alternatively, secre-
tion signal sequences could be added to both Aβ and affi-
body. These would be expected to be proteolyzed upon
secretion and Aβ would thereby obtain its native N-termi-
nus.
The 15N HSQC NMR spectra of MAβ and Aβ presented
here superimpose on those reported previously in studies
that thoroughly characterized Aβ as largely monomeric
under the applied experimental conditions [35,52]. This
is in agreement with the observation that purified MAβ
and Aβ adopt a predominantly random coil conformation
(Figure 4C). We conclude that MAβ is purified in non-
aggregated, monomeric form and applicable as starting
material for the investigation of fibril (Figure 4D) and oli-
gomer formation. The potential to obtain labeled peptide
makes MAβ suitable for structural studies by, e.g., NMR
spectroscopy. The coexpression system is compatible with
the overexpression of the highly aggregation prone Arctic
mutant of MAβ(1–42) and can therefore be utilized to
analyze the structural consequences of this and presuma-
bly other disease-related mutations of full-length Aβ(1–
42). Previous systematic NMR studies on clinically rele-
vant amino acid substitutions have pointed to a connec-
tion between monomer folding and oligomerization
propensity, but were limited to decapeptide segments of
Aβ [53].
Conclusion
We have described a recombinant expression system that
provides facile access to both major isoforms of the highly
amyloidogenic Aβ peptide by coexpression of an engi-
neered aggregation-inhibiting binding protein. The
method also allows for the production of the particularly
oligomerization and fibrillation-prone Arctic (E22G)
mutant of Aβ(1–42). The peptides are obtained in non-
aggregated, monomeric form and can be favorably
applied for the investigation of Aβ oligomerization and
fibrillation, inclusive of structural biology studies.
Methods
Cloning
The bacterial expression vector pACYCDuet-1 (Novagen)
is designed for the double cistronic coexpression of two
target genes and contains two multiple cloning sites
(MCS), each of which is preceded by a T7 promoter/lac
operator and a ribosome binding site. pACYCDuet-1
encoding Aβ(1–40) with an additional N-terminal
methionine, cloned as a NcoI/HindIII fragment at MCS 1,
was obtained from GENEART. The expression plasmid
pAY 442 encoding (His)6-tagged ZAβ3 [30] was digested
with NdeI and Bpu1102I (all enzymes supplied by New
England Biolabs), followed by insertion of the (His)6-ZAβ3
gene into MCS2 of pACYCDuet-1 at the respective restric-
tion sites. The resulting coexpression vector contains the
genes in the following order: T7 promoter-1 – MAβ(1–40)
– T7promoter-2 – (His)6ZAβ3 – T7 terminator. The vectors
for coexpression of MAβ(1–42) and MAβ(1–42)E22G
were generated by site-directed mutagenesis (Stratagene
QuikChange mutagenesis kit) of the MAβ(1–40) or
MAβ(1–42) expression clones, respectively.
Protein expression
BL21(DE3) E. coli cells (Novagen) were transformed with
the expression vectors and grown for ~16 h at 37°C on LB
agar plates containing 34 μg/mL chloramphenicol. Single
colonies were picked and grown for ~16 h in 20 mL 15N-
labeled M9 medium, containing 1 g/L 15NH4Cl, 2 g/L glu-
cose, 2 mM MgSO4, 0.1 mM CaCl2, 2 g/L natural 15N-Celt-
one powder (Spectra Stable Isotopes) and 34 μg/mL
chloramphenicol. The pre-culture was transferred to 1 L of
15N-labeled M9-Celtone medium in a 5 L baffled Erlen-
meyer flask. The culture was grown at 37°C with shaking
and induced at OD600 ~0.8 by the addition of IPTG to a
final concentration of 1 mM. After further growth for 4
hours the cells were harvested and frozen at -20°C. If iso-
topic labeling was not required, TB medium was used as
an alternative to M9-Celtone.
Purification of MAβ
The cell pellet from 1 L of bacterial culture was thawed in
an ice/water bath, resuspended in 15 mL of buffer A (50
mM sodium phosphate, 0.2 M sodium chloride, 1 mMBMC Biotechnology 2008, 8:82 http://www.biomedcentral.com/1472-6750/8/82
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PMSF, pH 7.2) and subjected to three freeze-thaw cycles,
followed by sonication according to a standard protocol.
The lyzed cells were clarified by centrifugation at 17,000 g
in a JA 25.50 rotor (Beckman) at 4°C for 30 min.
For capture of the MAβ:ZAβ3 complex by IMAC, the super-
natant was added to 10 mL HIS-Select Ni2+ affinity gel
(Sigma-Aldrich) equilibrated in buffer A, and the mixture
was incubated batch wise on a roller shaker for 20 min at
room temperature. Proteins not bound to the resin were
separated by centrifugation at 700 g for 5 min on a swing-
out rotor. The resin was washed twice with 50 mL of
buffer A, transferred to a 1.5 cm diameter Econo-Column
chromatography column (Bio-Rad Laboratories) and
washed with another 50 mL of buffer A and 50 mL of
buffer A supplemented with 10 mM imidazole. To sepa-
rate MAβ from the resin-bound ZAβ3, the drained resin was
resuspended in 40 mL of buffer SL (buffer A supple-
mented with 6 M guanidine hydrochloride (GdmCl), pH
7.2) and incubated for 30 min at room temperature. The
denatured MAβ peptide was recovered in the filtrate upon
filtration of the resin slurry through the Econo-Column
chromatography column.
Native MAβ was obtained by SEC of the denatured MAβ
on a Superdex 75 HR 10/300 column (GE Healthcare)
equilibrated with 20 mM sodium phosphate, 50 mM
sodium chloride, pH7.2. If protein concentration or stor-
age was desired, the pH of the SEC eluate was adjusted to
basic pH (~10.5) directly after elution, as basic pH pre-
serves the monomeric state of Aβ and is thus advanta-
geous for stock solutions [38,54]. Concentration of the
basic protein solutions was achieved using Vivaspin con-
centration columns (Sartorius). The identity of the pep-
tides was verified by mass spectrometry (MAβ(1–40),
theoretical mass: 4458.2 Da, experimental mass: 4458.1
Da; MAβ(1–42), theoretical mass: 4642.3 Da, experimen-
tal mass: 4642.3 Da). Peptide concentrations in solution
were measured by UV spectroscopy (ε280–ε300 = 1424 M-1
cm-1).
For analysis of the coexpressed MAβ:ZAβ3 complex, the
entire complex (i.e. without separation of the complex's
constituents under denaturing conditions) was eluted
from the IMAC column with buffer A supplemented with
150 mM imidazole, and subjected to SDS-PAGE (Figure 2,
lane 4). NMR measurements on the complex (Figure 3)
were carried out after an additional SEC step using a
Superdex 75 HR 10/300 column equilibrated with 20 mM
potassium phosphate, pH 7.2.
Aβ peptides
Aβ was obtained from a commercial source (rpeptide).
Aβ(1–40) was purchased either NaOH pre-treated or
HFIP pre-treated, dissolved in 30 mM ammonium
hydroxide to a concentration of 0.5 mM, and diluted into
the final experiment buffer. Aβ(1–42) was purchased
HFIP pre-treated. To ensure disaggregation of Aβ(1–42),
the peptide was dissolved in 6 M GdmCl (buffer SL) and
subjected to SEC, using the same conditions as employed
in the final step of the MAβ purification protocol.
Analytical size exclusion chromatography
Peptides at a concentration of 40–100 μM were analyzed
on a Superdex 75 HR 10/300 column equilibrated in 20
mM sodium phosphate, 50 mM sodium chloride, pH 7.2.
Elution profiles were normalized to unity at maximum
absorbance for the purpose of comparison.
Circular dichroism spectroscopy
Far-UV CD measurements were performed on a JASCO J-
810 spectropolarimeter using a 0.1 cm path length
cuvette. Peptides were used at concentrations of 20–25
μM in 20 mM phosphate, pH 7.2–7.4. Spectra were
recorded at 20°C. Thirty scans were averaged without
smoothing and corrected for the buffer spectrum.
Electron microscopy
Samples were applied to formvar/carbon coated nickel
grids, stained with 2% (w/v) uranyl acetate and viewed in
a LEO 912 AB Omega transmission electron microscope.
NMR spectroscopy
NMR was measured using Varian Inova 800 MHz and 900
MHz spectrometers. Samples of the MAβ:ZAβ3 complex
prepared after IMAC and SEC purification contained 160
μM complex in 20 mM potassium phosphate, pH 7.2,
with 10% D2O. Samples of purified MAβ and commercial
Aβ peptides contained ca. 60 μM 15N-labeled peptides in
20 mM sodium phosphate, 50 mM sodium chloride, pH
7.2, with 10% D2O. NMR data were processed using
NMRpipe [55] and analyzed using CcpNmr Analysis [56].
Thioflavin T amyloid formation assay
Thioflavin T fluorescence was recorded in 96-well plates
(Nunc) using a FLUOstar Optima reader (BMG) equipped
with 440 nm excitation and 480 nm emission filters. The
samples contained 100 ml of 25 μM MAβ(1–42) or Aβ(1–
42) in 20 mM Na-phosphate, 50 mM sodium chloride,
pH 7.2, supplemented with 10 μM thioflavin T. Plates
were sealed with polyolefin tape (Nunc) and incubated at
37°C. Data points were recorded every 10 min with 50 sec
of orbital shaking (width 5 mm) preceding each measure-
ment.
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